0
0
BRUSSELS — The European Medicines Agency (EMA) updated its safety guidelines on July 10, 2026, to warn that prolonged use of the progestogen-only contraceptive desogestrel is associated with a small increased risk of developing intracranial meningioma—a predominantly benign brain tumor. Crucially, the regulatory review brought reassuring news for millions of other contraceptive users: birth control pills and intrauterine devices (IUDs) containing the alternative progestogen, levonorgestrel, showed no such elevated risk. The safety update follows a rigorous regulatory review triggered by comprehensive, peer-reviewed epidemiological research tracking tens of thousands of women.
While the relative risk increase appears measurable after multiple years of continuous exposure, both regulatory bodies and independent experts emphasize that the absolute risk of developing these tumors remains very low.
Key Findings: The Data Driving the Safety Update
The safety signal stems primarily from a massive, real-world case-control study conducted by French researchers utilizing the French National Health Data System (Système National des Données de Santé, or SNDS). The findings, published in The BMJ, analyzed medical records of 8,391 women (with a mean age of approximately 60 years) who underwent surgery for intracranial meningioma between 2020 and 2023. Investigators compared these cases against 83,910 healthy, age-matched control subjects from the same regions.
The data revealed a clear distinction between the two studied progestogens:
-
Desogestrel (75 µg): Short-term use (less than one year) showed no increased odds of developing a tumor (Odds Ratio [OR] of 1.02). However, prolonged use was associated with an elevated risk (overall OR of 1.32). This risk was driven heavily by continuous long-term use, jumping to an OR of 1.51 for five to seven years of use, and climbing to 2.09 for seven or more continuous years.
-
Levonorgestrel: Reassuringly, the data showed no statistically significant or consistent association between levonorgestrel use—whether administered as a progestogen-only option or combined with estrogen—and meningioma risk, regardless of how long the patient used it.
Following a review by the EMA’s Pharmacovigilance Risk Assessment Committee (PRAC), the regulator announced that product information for desogestrel-containing products (often known as the “mini-pill”) will be updated to include meningioma as a potential side effect of unknown frequency, alongside new clinical contraindications.
Understanding Absolute vs. Relative Risk
To prevent public alarm, neuro-oncologists and public health specialists are contextualizing what these statistical “odds ratios” actually mean for an individual person. While an odds ratio of 2.09 sounds alarming—mathematically suggesting a doubling of the relative risk after seven years—the baseline occurrence of meningiomas is incredibly small.
Statisticians calculate this using the Number Needed to Harm (NNH). Based on the BMJ data, it is estimated that approximately 67,300 women would need to be treated with desogestrel across all durations for just one additional surgically treated intracranial meningioma to occur. For women currently using the drug continuously for more than five years, that number narrows to approximately one in 17,000.
“For the vast majority of patients, the absolute excess risk is negligible,” notes Dr. Alex Polyakov, a clinical associate professor at the University of Melbourne who was not involved in the study. “Meningiomas affect roughly one in 10,000 people in the general public. This added risk is small, and it sits against massive health benefits we too easily forget to mention: the prevention of unplanned pregnancies, lighter and less painful periods, and a reduced risk of ovarian and endometrial cancers.”
The Biological Context: Why Progestogens?
Meningiomas are slow-growing tumors that arise from the meninges—the protective layers of tissue surrounding the brain and spinal cord. Though roughly 90% of them are non-cancerous (benign), they can become serious or require neurosurgical intervention if they press against vital brain structures, leading to symptoms like vision changes, hearing loss, headaches, or loss of balance.
Medical science has long recognized that meningiomas are highly hormone-sensitive. They frequently express progesterone receptors on their surface, and it is well-documented that these tumors can rapidly enlarge during pregnancy when natural progesterone levels spike.
Prior clinical research had already firmly linked older, high-dose progestogens—such as cyproterone acetate, medroxyprogesterone acetate, and nomegestrol acetate—to increased meningioma risks, prompting strict prescribing limits. Because of those historical findings, researchers initiated this closer look at newer, lower-dose, everyday contraceptives like desogestrel and levonorgestrel to see if the class effect extended to them.
Study Limitations and Expert Caveats
While the French cohort study is praised for its size and rigorous use of national data, independent experts urge caution regarding its observational nature. Because it is an observational study, it can establish a statistical association but cannot definitively prove a direct cause-and-effect relationship.
Several limitations must be taken into account:
-
Prior Hormone Exposure: The risk was significantly more pronounced (an OR of 3.30) in women who had previously used older, high-risk progestogens in the years before switching to desogestrel. Separating the exact biological culprit remains difficult.
-
Confounding Factors: The database lacked granular information regarding patients’ genetic predispositions or historical exposure to high-dose radiation (a known environmental risk factor for meningiomas).
-
Age and Location: The elevated risk was concentrated primarily in older women (those over 45) and specifically involved tumors forming at the middle or anterior skull base.
Encouragingly, the data revealed a rapid reversal of risk: the statistical excess completely disappeared within one year of stopping desogestrel. In a linked medical editorial, neurosurgeon Gilles Reuter pointed out that because hormone-induced meningiomas often shrink spontaneously once the offending hormone is withdrawn, recognizing this side effect early could allow patients to skip immediate brain surgery entirely, opting instead for conservative monitoring.
Public Health Implications: What Should Patients Do?
The EMA’s updated mandate establishes that desogestrel- and etonogestrel-containing medicines are now strictly contraindicated in women who have a current meningioma or a history of the condition. Furthermore, clinicians are advised to routinely review the necessity of continued therapy for patients on desogestrel, particularly once they cross the five-year mark of continuous use.
For everyday health-conscious consumers, the universal message from the medical community is to avoid panic. Women are strongly urged not to abruptly discontinue their birth control pills, as sudden cessation carries an immediate risk of unintended pregnancy or severe menstrual issues.
Instead, individuals who have been taking desogestrel for several years should schedule a routine consultation with their physician or family planning clinic. For those who are starting contraception fresh, or who prefer a long-term approach with zero statistical brain tumor correlation, clinicians can easily discuss alternative options like levonorgestrel-based pills or low-dose hormonal IUDs, which the data reaffirmed as entirely safe in this context.
Reference Section
- https://www.reuters.com/business/healthcare-pharmaceuticals/eu-regulator-warns-small-brain-tumor-risk-with-desogestrel-etonogestrel-2026-07-10/
Medical Disclaimer: This article is for informational purposes only and should not be considered medical advice. Always consult with qualified healthcare professionals before making any health-related decisions or changes to your treatment plan. The information presented here is based on current research and expert opinions, which may evolve as new evidence emerges.
